Literature DB >> 29894383

Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.

Kaelo K Seatla1,2,3, Ava Avalos4,3,5, Sikhulile Moyo1,6, Madisa Mine1,4, Thabo Diphoko1,2, Mosepele Mosepele1,7,3, Tendani Gaolatlhe1,7, Christopher F Rowley6, Dinah Ramaabya4, Joseph N Jarvis1,7,3,8, Ishmael Kasvosve2, Simani Gaseitsiwe1,6.   

Abstract

: There are limited data on the effectiveness of dolutegravir (DTG)-based combination antiretroviral therapy (ART) in real-life settings in southern Africa where HIV-1 subtype C predominates. We report a patient infected with HIV-1 subtype C on DTG-based ART previously exposed to raltegravir who developed multidrug resistance mutations to four antiretroviral classes. There is need for drug resistance monitoring and clinical vigilance to ensure effectiveness of HIV treatment programs even in the era of DTG-based ART.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29894383      PMCID： PMC7255068          DOI： 10.1097/QAD.0000000000001920

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  9 in total

1.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

2.  Bioinformatics prediction of HIV coreceptor usage.

Authors:  Thomas Lengauer; Oliver Sander; Saleta Sierra; Alexander Thielen; Rolf Kaiser
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

3.  Update of the drug resistance mutations in HIV-1: March 2013.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Gunthard; Roger Paredes; Deenan Pillay; Robert W Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2013 Feb-Mar

Review 4.  Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.

Authors:  Carole L Wallis; Catherine Godfrey; Joseph E Fitzgibbon; John W Mellors
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

5.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

6.  Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Authors:  Alison J Rodger; Valentina Cambiano; Tina Bruun; Pietro Vernazza; Simon Collins; Jan van Lunzen; Giulio Maria Corbelli; Vicente Estrada; Anna Maria Geretti; Apostolos Beloukas; David Asboe; Pompeyo Viciana; Félix Gutiérrez; Bonaventura Clotet; Christian Pradier; Jan Gerstoft; Rainer Weber; Katarina Westling; Gilles Wandeler; Jan M Prins; Armin Rieger; Marcel Stoeckle; Tim Kümmerle; Teresa Bini; Adriana Ammassari; Richard Gilson; Ivanka Krznaric; Matti Ristola; Robert Zangerle; Pia Handberg; Antonio Antela; Sris Allan; Andrew N Phillips; Jens Lundgren
Journal:  JAMA       Date:  2016-07-12       Impact factor: 56.272

7.  Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.

Authors:  Antonella Castagna; Franco Maggiolo; Giovanni Penco; David Wright; Anthony Mills; Robert Grossberg; Jean-Michel Molina; Julie Chas; Jacques Durant; Santiago Moreno; Manuela Doroana; Mounir Ait-Khaled; Jenny Huang; Sherene Min; Ivy Song; Cindy Vavro; Garrett Nichols; Jane M Yeo
Journal:  J Infect Dis       Date:  2014-01-19       Impact factor: 5.226

8.  Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts.

Authors:  Rimke Bijker; Awachana Jiamsakul; Cissy Kityo; Sasisopin Kiertiburanakul; Margaret Siwale; Praphan Phanuphak; Sulaimon Akanmu; Romanee Chaiwarith; Ferdinand W Wit; Benedict Lh Sim; Tamara Sonia Boender; Rossana Ditangco; Tobias F Rinke De Wit; Annette H Sohn; Raph L Hamers
Journal:  J Int AIDS Soc       Date:  2017-03-03       Impact factor: 5.396

Review 9.  Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa.

Authors:  Natasha Croome; Monisha Ahluwalia; Lyndsay D Hughes; Melanie Abas
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177
  9 in total
  10 in total

1.  Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.

Authors:  Emmanuel Ndashimye; Mariano Avino; Abayomi S Olabode; Art F Y Poon; Richard M Gibson; Yue Li; Adam Meadows; Christine Tan; Paul S Reyes; Cissy M Kityo; Fred Kyeyune; Immaculate Nankya; Miguel E Quiñones-Mateu; Eric J Arts
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

2.  High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.

Authors:  Emmanuel Ndashimye; Yue Li; Paul S Reyes; Mariano Avino; Abayomi S Olabode; Cissy M Kityo; Fred Kyeyune; Immaculate Nankya; Miguel E Quiñones-Mateu; Stephen D Barr; Eric J Arts
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.758

3.  A systematic review of the genetic mechanisms of dolutegravir resistance.

Authors:  Soo-Yon Rhee; Philip M Grant; Philip L Tzou; Geoffrey Barrow; P Richard Harrigan; John P A Ioannidis; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

4.  Resistance in patients failing integrase strand transfer inhibitors: a call to replace raltegravir with dolutegravir in third-line treatment in South Africa.

Authors:  Kim Steegen; Gert van Zyl; Esrom Letsoalo; Mathilda Claassen; Lucia Hans; Sergio Carmona
Journal:  Open Forum Infect Dis       Date:  2019-08-21       Impact factor: 3.835

Review 5.  Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies.

Authors:  Aurélie Delannoy; Mikaël Poirier; Brendan Bell
Journal:  Viruses       Date:  2019-03-18       Impact factor: 5.048

6.  A case report of untreatable HIV infection in Harare, Zimbabwe.

Authors:  Cleophas Chimbetete; Linda Chirimuta; Margaret Pascoe; Olivia Keiser
Journal:  South Afr J HIV Med       Date:  2019-06-27       Impact factor: 2.744

7.  Adherence to Antiretroviral Therapy and Associated Factors Among People Living With HIV Following the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania.

Authors:  Mary Spicar Kilapilo; Raphael Zozimus Sangeda; George M Bwire; Godfrey Leonard Sambayi; Idda Hubert Mosha; Japhet Killewo
Journal:  J Int Assoc Provid AIDS Care       Date:  2022 Jan-Dec

8.  HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.

Authors:  Kaelo K Seatla; Dorcas Maruapula; Wonderful T Choga; Tshenolo Ntsipe; Nametso Mathiba; Mompati Mogwele; Max Kapanda; Bornapate Nkomo; Dinah Ramaabya; Joseph Makhema; Mompati Mmalane; Madisa Mine; Ishmael Kasvosve; Shahin Lockman; Sikhulile Moyo; Simani Gaseitsiwe
Journal:  Viruses       Date:  2021-03-31       Impact factor: 5.048

9.  Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.

Authors:  Kaelo K Seatla; Wonderful T Choga; Mompati Mogwele; Thabo Diphoko; Dorcas Maruapula; Lucy Mupfumi; Rosemary M Musonda; Christopher F Rowley; Ava Avalos; Ishmael Kasvosve; Sikhulile Moyo; Simani Gaseitsiwe
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

10.  First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.

Authors:  Joseph Fokam; Desire Takou; Ezechiel Ngoufack Jagni Semengue; Georges Teto; Grace Beloumou; Beatrice Dambaya; Maria-Mercedes Santoro; Leonella Mossiang; Serge Clotaire Billong; Fatim Cham; Samuel Martin Sosso; Edith Saounde Temgoua; Aubin Joseph Nanfack; Sylvie Moudourou; Nelly Kamgaing; Rachel Kamgaing; Joelle Nounouce Ngako Pamen; Mireille Mpoudi Ngole Etame; Anne-Cecile Z-K Bissek; Jean-Bosco N Elat; Emmanuel Eben Moussi; Vittorio Colizzi; Carlo-Federico Perno; Alexis Ndjolo
Journal:  Antimicrob Resist Infect Control       Date:  2020-08-26       Impact factor: 4.887
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.